Sequenom in Discussions with FDA on Premarket Application for Sequencing-Based Trisomy 21 Test
March 16, 2011
Sequenom in Discussions with FDA on Premarket Application for Sequencing-Based Trisomy 21 Test
CEO Harry Hixson said that the company had its first meeting with the FDA regarding the test in January, and while he could not comment on specifics of the meeting, in response to an investor question, he said that "it's safe to say that [the FDA] has not raised any concerns."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With Clinical Validation Study Complete, Sequenom Moves Ahead with 2012 Launch of T21 Test
May 10, 2011 / Clinical Sequencing News - Sequenom Runs More Than 13K T21 Tests in Q2; Plans to Expand Capacity in US and Overseas
August 1, 2012 / Clinical Sequencing News - As MaterniT21 Drives Spike in Diagnostic Revenue, Sequenom Predicts 25K Tests Sold in 2012
March 14, 2012 / Clinical Sequencing News - Sequenom Launches MaterniT21 Down Syndrome Test as LDT, Publishes Clinical Validation Study
October 19, 2011 / Clinical Sequencing News - Verinata Licenses Quake Patent, Setting Stage for IP Tussle with Sequenom
September 7, 2011 / Clinical Sequencing News